Smoking Cessation Labels Cleared Without Duration-Of-Use Limit
This article was originally published in The Tan Sheet
Executive Summary
FDA approved labeling for Nicorette and NicoDerm CQ nicotine replacement therapies, removing some risk information that industry and the agency agree is outdated and unnecessarily restrictive.
You may also be interested in...
Will Novel NRT Interest Heat Up In US With First Clearance For ENDS Under Tobacco Control Act?
Without mentioning NRT space, FDA’s acceptance of one vape device and two replacement nicotine cartridges as tobacco products might reignite interest in proposals for ENDS or other novel products to be approved for smoking cessation claims. To gain clearance as tobacco products, the ENDS were shown to provide a benefit similar to efficacies required for an NRT.
E-cigarette NRT Outlook Heated By Combining With Counseling, Nicotine-Tapering Strategy
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
NRT Delivery Innovation Proposal In US Doesn't Deliver Expanded Indications
GSK's proposed usage for mouth spray product – reducing withdrawal symptoms, including nicotine craving – differs little from the first NRT product approved in US in 1984. Additional suggested label instructions primarily focus on stating NRTs can be used to reduce smoking or gradually stop tobacco use as opposed to quitting within a specified amount of time.